» Articles » PMID: 35154524

Factors Associated with Gastro-duodenal Ulcer in Compensated Type 2 Diabetic Patients: a Romanian Single-center Study

Overview
Journal Arch Med Sci
Specialty General Medicine
Date 2022 Feb 14
PMID 35154524
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: infection is accepted as the leading cause of chronic gastritis, ulcer disease and gastric cancer, with an important impact on health care burden, especially in countries with a high prevalence of infection. The aim of the study was to investigate the influence of infection, medication, associated medical conditions or social habits on endoscopic ulcer occurrence in the compensated type 2 diabetic population.

Material And Methods: Two hundred and sixty type 2 diabetic patients investigated on endoscopy (57 patients with peptic ulcer and 203 controls) with a complete set of biopsies, demographic and medical data were enrolled.

Results: On univariate regression analysis, infection (42.1% vs. 35.5%, = 0.359) or a history of peptic ulcer (61.4% vs. 61.6%, = 0.981) was not a predictor for ulcer on endoscopy in the diabetic population, and heartburn was more frequent in diabetics without ulcer (21.2% vs. 8.8%, = 0.033). Anemia was the best predictor for ulcer on endoscopy in both diabetics with ( < 0.001, OR = 4.77, 95% CI: 2.02-11.28) and without ( = 0.027, OR = 2.76, 95% CI: 1.10-6.91) chronic proton pump inhibitor (PPI) therapy. In diabetic patients on PPI more than 1 month anticoagulants - acenocoumarol or low-weight molecular heparin ( = 0.038, OR = 2.37, 95% CI: 1.04-5.40), low-dose aspirin 75-125 mg/day ( = 0.029, OR = 2.61, 95% CI: 1.08-6.28) and alcohol consumption ( = 0.015, OR = 2.70, 95% CI: 1.19-6.13) were predictors for ulcer on endoscopy.

Conclusions: In diabetic patients, anemia is the most important predictor for ulcer on endoscopy, but not or digestive symptoms, while low-dose aspirin or anticoagulant therapy and alcohol consumption are the most important predictors for ulcer in diabetics on chronic proton pump inhibitor therapy.

Citing Articles

A real-world retrospective study of omeprazole-domperidone combination in managing acid peptic disease with PRoton-pump Inhibitors in patients with type 2 DiabEtes mellitus (PRIDE-2).

Saboo B, Mulwani N, Petare A, Veligandla K, Pinto C, Mane A Drugs Context. 2023; 12.

PMID: 36816461 PMC: 9933899. DOI: 10.7573/dic.2022-10-3.

References
1.
Ramphul K, Gonzalez Mejias S . Kawasaki disease: a comprehensive review. Arch Med Sci Atheroscler Dis. 2019; 3:e41-e45. PMC: 6374576. DOI: 10.5114/amsad.2018.74522. View

2.
Negovan A, Iancu M, Moldovan V, Voidazan S, Bataga S, Pantea M . Clinical Risk Factors for Gastroduodenal Ulcer in Romanian Low-Dose Aspirin Consumers. Gastroenterol Res Pract. 2016; 2016:7230626. PMC: 4992789. DOI: 10.1155/2016/7230626. View

3.
Bhatt D, Scheiman J, Abraham N, Antman E, Chan F, Furberg C . ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation. 2008; 118(18):1894-909. DOI: 10.1161/CIRCULATIONAHA.108.191087. View

4.
Haj S, Chodick G, Refaeli R, Goren S, Shalev V, Muhsen K . Associations of Helicobacter pylori infection and peptic disease with diabetic mellitus: Results from a large population-based study. PLoS One. 2017; 12(8):e0183687. PMC: 5574557. DOI: 10.1371/journal.pone.0183687. View

5.
He C, Yang Z, Lu N . Helicobacter pylori infection and diabetes: is it a myth or fact?. World J Gastroenterol. 2014; 20(16):4607-17. PMC: 4000497. DOI: 10.3748/wjg.v20.i16.4607. View